Brief: CervoMed Announces Alignment With FDA On Registration Path For Neflamapimod In Dementia With Lewy Bodies
04/11/2025 12:36
Nov 4 (Reuters) - CervoMed Inc CRVO.O: CERVOMED ANNOUNCES ALIGNMENT WITH FDA ON REGISTRATION PATH FOR NEFLAMAPIMOD IN DEMENTIA WITH LEWY BODIES CERVOMED INC: ADVANCING PREPARATIONS FOR GLOBAL PIVOTAL TRIAL INITIATION IN SECOND HALF OF 2026 CERVOMED INC - TO INITIATE GLOBAL PHASE 3 TRIAL FOR NEFLAMAPIMOD IN 2026 Source text: ID:nGNXmfKkQ Further company coverage: CRVO.O ((Reuters.Briefs@thomsonreuters.com;))